Edition:
United States

Express Scripts Holding Co (ESRX.O)

ESRX.O on Nasdaq

62.68USD
1:36pm EDT
Change (% chg)

$0.39 (+0.63%)
Prev Close
$62.29
Open
$62.17
Day's High
$63.15
Day's Low
$62.00
Volume
1,377,290
Avg. Vol
3,477,696
52-wk High
$77.50
52-wk Low
$57.80

Latest Key Developments (Source: Significant Developments)

Express Scripts CEO Timothy Wentworth's FY 2016 total compensation $14.5 mln vs $8.5 mln
Friday, 17 Mar 2017 04:07pm EDT 

Express Scripts Holding Co : Express scripts holding co - ceo timothy wentworth's fy 2016 total compensation $14.5 million versus $8.5 million in fy 2015 - sec filing .Express scripts holding co - former ceo george paz's fy 2016 total compensation $11.9 million versus $14.8 million in fy 2015.  Full Article

Express Scripts chief medical officer says Mylan has a monopoly on the EpiPen
Thursday, 25 Aug 2016 04:03pm EDT 

: Express Scripts Chief Medical Officer Steve Miller On Mylan Epipen Price Hike - "Mylan could lower the price today" . Express Scripts Chief Medical Officer Steve Miller On Mylan Epipen Price Hike - Mylan has a monopoly on the epipen Further company coverage: [MYL.O ESRX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 09:01pm EDT 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

Horizon pharma says it continues to have discussions with Express Scripts
Monday, 1 Aug 2016 03:56pm EDT 

Horizon Pharma : Continues to have discussions with express scripts and sees potential pathway to completion of potential partnership with express scripts beginning 2017 .Recognizes express scripts published formulary exclusion list, which will take effect on january 1, 2017, includes duexis and vimovo.  Full Article

Express Scripts Q2 earnings per share $1.13
Monday, 25 Jul 2016 04:59pm EDT 

Express Scripts Holding Co : Says Q2 revenue $25.22 billion versus $25.45 billion . Sees Q3 total adjusted claims 311 million to 321 million . Year adjusted diluted eps guidance range; raises mid-point; provides 2016 third quarter guidance . Q2 earnings per share $1.13 . Q2 earnings per share view $1.57 -- Thomson Reuters I/B/E/S . Sees FY 2016 adjusted earnings per share $6.33 to $6.43 . Q2 adjusted earnings per share $1.57 . Says Q2 adjusted claims of 315.3 million . Says narrows 2016 adjusted earnings per diluted share guidance to a range of $6.33 to $6.43 . Sees Q3 adjusted diluted earnings per share $1.72 to $1.76 .FY 2016 earnings per share view $6.35; q3 earnings per share view $1.72 -- Thomson Reuters I/B/E/S.  Full Article

Express Scripts Holding Co increases authorization for share repurchase program
Thursday, 3 Dec 2015 04:01pm EST 

Express Scripts Holding Co:Increases authorization for share repurchase program.Approved increase in number of shares that may be repurchased under share repurchase program by 60 million shares.  Full Article

Express Scripts Holding Co raises FY 2015 EPS guidance
Tuesday, 27 Oct 2015 04:01pm EDT 

Express Scripts Holding Co:Raised and narrowed its FY 2015 adjusted diluted earnings per share guidance from a range of $5.46 to $5.54 to a range of $5.51 to $5.55, which represents growth of 13% to 14% over FY 2014.FY 2015 EPS of $5.50 - Thomson Reuters I/B/E/S.  Full Article

Express Scripts wins dismissal of lawsuit over Anthem ties

NEW YORK A federal judge has dismissed a lawsuit in which Express Scripts Holding Co shareholders accused the pharmacy benefits manager of inflating its share price by hiding its deteriorating relationship with its largest customer, Anthem Inc.